Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer

Annals of Nuclear Medicine

Volumn 19, Issue 3, 2005, Pages 247-250

  Rosário, Pedro Wesley Souza ^a,b   Barroso, Álvaro L ^a   Rezende, Leonardo L ^a   Padrão, Eduardo L ^a   Fagundes, Tales A ^a   Reis, Janice S ^a   Purisch, Saulo ^a  

^a Nuclear Medicine and Endocrinology Service   (Brazil)

^b Centro de Estudos e Pesquisa   (Brazil)

Author keywords

Ablation; Thyroid remnants

Indexed keywords

IODINE 131; THYROGLOBULIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CATHETER ABLATION; CELL DIFFERENTIATION; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENDER; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; RADIOIODINATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THYROID CANCER; THYROID CELL; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 21044457149     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984614     Document Type: Article

References (37)

1. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-424.
2. Mazzaferri EL, Kloos R. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447-1463.
3. Schlumberger MJ. Medical progress-papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
4. 131I in the treatment of patients with differentiated thyroid cancer? Nucl Med Commun 1996; 17: 199-207.
5. Rosario PW, Reis JS, Barroso AL, Rezende LL, Padrão EL, Fagundes TA. Efficacy of low and high iodine-131 doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on postoperative cervical uptake. Nucl Med Commun 2004; 25: 1077-1081.
6. 131iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol 1998; 47: 325-330.
7. DeGroot LJ, Reilly M. Comparison of 30 and 50 mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 1992; 96: 51-53.
8. Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33: 1132-1136.
9. 131I dose in differentiated thyroid cancer. Clin Endocrinol 2000; 52: 765-773.
10. Roos DE, Smith JG. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma -a critique. Int J Rad Oncol Bio Phys 1999; 44: 493-495.
11. Gawkowska-Suwinska M, Turska M, Roskosz J, Puch Z, Jurecka-Tuleja B, Handkiewicz-Junak D, et al. Early evaluation of treatment effectiveness using 131 iodine radiotherapy in patients with differentiated thyroid cancer. Wiad Lek 2001; 54: 278-288.
12. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 1984; 25: 1287-1293.
13. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? J Clin Endocrinol Metab 2000; 85: 175-178.
14. Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin 1998; 37: 23-25.
15. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodine on the uptake of ablative dose of iodine-131. Thyroid 1994; 4: 49-54.
16. Leger FA, Izembart M, Dagousset F. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25: 242-246.
17. Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998; 39: 1546-1550.
18. 131I. Nucl Med Commun 1996; 17: 839-842.
19. Park H, Park Y, Zhou X. Detection of thyroid remnant/ metastasis without stunning: An ongoing dilemma. Thyroid 1997; 7: 277-280.
20. Waxman A, Ramanna L, Chapman N, Chapman D, Brachman M, Tanasescu D, et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation [concise communication]. J Nucl Med 1981; 22: 861-865.
21. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18: 505-512.
22. 131I. J Nucl Med 2000; 41: 1198-1202.
23. 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001; 86: 3507-3535.
24. 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77: 2574-2580.
25. Arslan N, Ilgan S, Serdengecti M, Ozguven MA, Bayhan H, Okuyucu K, et al. Post-surgical ablation of thyroid remnants with high-dose (131)I in patients with differentiated thyroid carcinoma. Nucl Med Commun 2001; 22: 1021-1027.
26. Arad E, Flannery K, Wilson GA, O'Mara RE. Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants. Clin Nucl Med 1990; 15: 676-677.
27. Wang SJ, Liu TJ. Use of fractionated doses of iodine-131 for ablation of thyroid remnants. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 65: 336-340.
28. Verkooijen RB, Stokkel MP, Smit JW, Pauwels EK. Radio-iodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy. Eur J Nucl Med Mol Imaging 2004; 31: 499-506.
29. Logue JP, Tsang RW, Brierley JD, Simpson WJ. Radio-iodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Br J Radiol 1994; 67: 1127-1131.
30. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun 2003; 24: 489-495.
31. 131I in patients with differentiated thyroid cancers. Wiad Lek 2001; 54: 363-367.
32. Attie JN, Moskowitz GW, Margouleff D, Levy LM. Feasibility of total thyroidectomy in the treatment of thyroid carcinoma: postoperative radioactive iodine evaluation of 140 cases. Am J Surg 1979; 138: 555-560.
33. Wloch J, Czarniecka A. Early evaluation of results after total thyroidectomy in patients with thyroid cancer. Wiad Lek 2001; 54: 210-217.
34. Clark OH. Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. Ann Surg 1982; 196: 361-370.
35. Schwartz AE, Friedman EW. Preservation of the parathyroid glands in total thyroidectomy. Surg Gynecol Obstet 1987; 165: 327-332.
36. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87: 1499-1501.
37. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87: 3242-3247.